Crowley, J., Thaçi, D., Joly, P., Peris, K., Papp, K. A., Goncalves, J., . . . Cather, J. C. (2017). Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). Journal of the American Academy of Dermatology, 77(2), 310-317.e1. https://doi.org/10.1016/j.jaad.2017.01.052
Citace podle Chicago (17th ed.)Crowley, Jeffrey, et al. "Long-term Safety and Tolerability of Apremilast in Patients with Psoriasis: Pooled Safety Analysis for ≥156 weeks from 2 Phase 3, Randomized, Controlled Trials (ESTEEM 1 and 2)." Journal of the American Academy of Dermatology 77, no. 2 (2017): 310-317.e1. https://doi.org/10.1016/j.jaad.2017.01.052.
Citace podle MLA (9th ed.)Crowley, Jeffrey, et al. "Long-term Safety and Tolerability of Apremilast in Patients with Psoriasis: Pooled Safety Analysis for ≥156 weeks from 2 Phase 3, Randomized, Controlled Trials (ESTEEM 1 and 2)." Journal of the American Academy of Dermatology, vol. 77, no. 2, 2017, pp. 310-317.e1, https://doi.org/10.1016/j.jaad.2017.01.052.